glp-1 news october 1 2025 As Drugs Go Mainstream, This Expert Says Health is More than a Number on a Scale How Employers Can Manage GLP-1

Independent editorial review, not affiliated

Diabetes leads to a significantly accelerated incidence of various related macrovascular complications, including peripheral vascular disease and cardiovascular disease (the most common cause of mortality in diabetes), as well as microvascular complications such as kidney disease and retinopathy

Grateful if you can share this

[What percent of these changes were due to the post-Dobbs SCOTUS decision and State-level policy decisions, we do not yet know]

Study finds that individuals who took GLP-1 agonists for a long duration had a lower risk of going on to develop more severe forms of liver disease, including cirrhosis and liver cancer.

macro-dosing.